The Defense Threat Reduction Agency has awarded MeMed a $9.2 million contract to fund development work on a medical technology designed to help clinicians diagnose bacterial and viral infections at the point of care.
The company said Wednesday it has teamed up with several researchers and clinicians worldwide in efforts to create a human immune signature that will work to recognize differences between bacterial and viral infections.
“This joint effort, and our growing collaboration with other international stakeholders from industry and government, will facilitate the global availability of our tests aimed at combating antimicrobial resistance,” said MeMed CEO Eran Eden.
“The project will also evaluate and expand our test menu to detect early infections, even at the pre-symptomatic stage of a disease – currently a major challenge in our ability to control infections and epidemics,” said Tanya Gottlieb, vice president of scientific affairs at MeMed.
MeMed noted its ImmunoXpert test has been validated in thousands of patients and a second generation of the platform is designed to help clinicians perform tests within a 15-minute period.